Unlocking the Potential of IGHV3-64D as a Drug Target and Biomarker

Target Name: IGHV3-64D

NCBI ID: G102723170

IGHV3-64D

Other Name(s): immunoglobulin heavy variable 3-64D | Immunoglobulin heavy variable 3-64D

Unlocking the Potential of IGHV3-64D as a Drug Target and Biomarker

Immunoglobulin heavy variable (IgHV) 3-64D is a type of antibody that plays a crucial role in protecting the body against various infections and diseases. The identification and characterization of new drug targets and biomarkers for IGHV-3-64D have the potential to revolutionize the field of immunology and the development of new treatments. In this article, we will explore the potential of IGHV-3-64D as a drug target and biomarker, highlighting its unique features and the current research in this field.

Structure and Function

IgHV-3-64D is a type of IgHV fragment that consists of the constant region (C1), the variable region (V1-32), and the variable region (V33-64). It has a molecular weight of approximately 180 kDa and a monomeric structure. The IGHV-3-64D molecule is composed of two heavy chains and two light chains that are held together by disulfide bonds.

The IGHV-3-64D molecule has several unique features that make it an attractive drug target and biomarker. One of its main advantages is its high expression level in various tissues and body fluids, including blood, lymphoid tissue, and organs. Its relatively constant expression level also indicates that it is less likely to be regulated by cytokines, making it a more stable target for drugs.

Another key feature of IGHV-3-64D is its unique antigenic variation. Unlike other IgHVs, IGHV-3-64D has a variable region that is highly diverse. This diversity allows for the production of a wide range of antibody subtypes, making it more difficult to develop monoclonal antibodies (Mabs) against it. This is a potential advantage for drug development, as researchers can target individual subtypes of IGHV-3-64D to prevent the development of cross-resistance.

Drug Target Potential

The high expression level and unique features of IGHV-3-64D make it an attractive drug target. Drugs that can inhibit its function or interact with its structure can potentially lead to the development of new treatments for various diseases.

One potential mechanism by which IGHV-3-64D can be targeted is its role in inflammation. IGHV-3-64D is a component of the adaptive immune response and has been implicated in the regulation of inflammation. Its functions in this context include the regulation of T cell proliferation and the production of antibodies that contribute to the development of immune-mediated diseases.

In addition to its role in inflammation, IGHV-3-64D has also been shown to play a key role in cancer progression. Its functions in this context include the regulation of cell proliferation, the development of cancer stem cells, and the regulation of apoptosis.

Biomarker Potential

The unique features of IGHV-3-64D make it an attractive biomarker for various diseases. Its high expression level and the diversity of its variable region make it difficult to develop Mabs against it. This makes it a potential candidate for use in monoclonal antibody-based diagnostic tests.

One potential application of IGHV-3-64D as a biomarker is its use in the diagnosis of autoimmune diseases. These diseases are characterized by the production of antibodies that autoimmune tissues, leading to inflammation and damage to the body's tissues. IGHV-3-64D has been shown to be highly expressed in the tissues of individuals with a variety of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

IGHV-3-64D has also been shown to be highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that it may be a useful biomarker for the

Protein Name: Immunoglobulin Heavy Variable 3-64D

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV3-64D Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV3-64D comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets